Trial Profile
A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Antineoplastics
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Dec 2021 Status changed from active, no longer recruiting to completed.
- 29 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 11 Feb 2019 According to a Bristol-Myers Squibb media release, based on the data from this trial, European Commission (EC) has approved Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).